CBIO
Crescent Biopharma, Inc.
Healthcare — Biotechnology
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Strong Buy
1.4 / 5
5 analysts
$14.26
$-0.33 (-2.26%)
Target:
$31.00
(117.4%)
Price History
52-Week Range
Sign in to add CBIO to a watchlist or set price alerts.
Fundamentals
| Market Cap | $470.98M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.80 |
| EPS (TTM) | $-5.88 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 0.84 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $31.00 |
| Analysts | 5 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 46.1 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| 50-Day Avg | $19.49 |
| 200-Day Avg | $14.47 |
| Avg Volume | 355.8K |
| Volume | 323.9K |
Performance Analysis
NEUTRALCBIO presents a mixed picture with both positive and negative indicators.
~
Trading at 30% of its 52-week range.
~
RSI at 46.1 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 5 analysts.
+
Average analyst target of $31.00 implies 117.4% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:02 UTC
Back to Screener Export Report